Nuclear factor B (NF-B) is a widely expressed transcription factor of particular importance to the regulation of cells of the immune system (1) . NF-B encompasses a family of inducible transcription factors including RelA/p65, RelB, c-Rel, p50, and p52 (1) . These proteins share a conserved 300-amino acid region within their amino termini, designated Rel-homology domain (RHD). This domain is responsible for dimerization, nuclear translocation, DNA binding, and interaction with heterologous transcription factors (1) . NF-B is composed of homo-or heterodimers with a range of DNA binding and activation potentials. The most abundant and best-studied form of NF-B in cells is a heterodimer consisting of the two subunits, p50 (NF-B1) and p65 (RelA). NF-B plays a key role in the regulation of many genes involved in mammalian immune and inflammatory responses, apoptosis, cell proliferation, and differentiation (1, 2) . NF-B has additionally been associated with neurodegenerative processes and cancer (3, 4) . In unstimulated cells, NF-B is sequestered in the cytoplasm as an inactive transcription factor complex by its physical association with one of several inhibitors of NF-B (IBs) 2 (5) . Treatment of cells with extracellular stimuli including cytokines, bacterial lipopolysaccharides (LPS), phorbol esters, or potent oxidants leads to rapid phosphorylation of IB␣, which results in ubiquitination of IB␣ and subsequent degradation by the 26 S proteasome (4, 5) . Dissociation of NF-B unmasks the nuclear localization sequences of p65 and p50 subunits, which leads to nuclear translocation and binding of NF-B to specific B consensus sequences in the chromatin and activation of specific subsets of genes (3) .
NF-B-dependent gene expression requires growing families of transcriptional coactivators (6, 7) . The two key coactivators of NF-B, histone acetyltransferases p300 and its homolog, the cAMP-response element-binding protein (CREB)-binding protein (CBP), directly associate with the NF-B subunits p50 and p65 (8 -10) . These coactivators are thought to promote the rapid formation of the pre-initiation and re-initiation complexes by bridging the sequence-specific activators (like NF-B) to the basal transcription machinery, thereby facilitating multiple rounds of transcription (11) . Additionally, the histone acetyltransferases p300 and CBP can modify the amino-terminal tails of nucleosomal histones, thereby altering the local chromatin structure (12) (13) (14) . Although the recruitment of p300 or CBP to NF-B-dependent enhanceosomes is required for synergistic activation, tethering p300/CBP alone to the promoter through NF-B is not sufficient for full activity of NF-B in the context of chromatin. Several reports indicated that the combined actions and interactions of distinct transcriptional coactivator complexes and cofactors seem to be attributable to the strong transcriptional activity of NF-B, depending on the stimuli and the cell type (6, 8, 15, 16) .
Poly(ADP-ribose) poly-merase-1 (PARP-1) is a nuclear chromatinassociated protein and belongs to a large family of enzymes that can synthesize polymers of ADP-ribose units by using ␤-nicotinamide adenine dinucleotide (NAD ϩ ) as substrate (17) . PARP-1 and NF-B have both been suggested to play a pathophysiological role in a number of inflammatory disorders (17) . Several studies showed that PARP-1(Ϫ/Ϫ) mice were protected against myocardial infarction, streptozotocin-induced diabetes, LPS-induced septic shock, zymosan-induced vascular failure, a non-septic model of multiple organ dysfunction as well as collagen-induced arthritis. This indicates that PARP-1 has a vital role in inflammatory disorders (17) . PARP-1 has been suggested to act as a promoter-specific coactivator of NF-B in these inflammatory disorders (18) . Indeed, up-regulation of subsets of inflammatory mediators such as TNF␣, IFN␥, and iNOS was shown to be impaired in PARP-1(Ϫ/Ϫ) mice upon treatment with LPS, zymosan, or streptozotocin (17, 19) . We recently presented evidence that PARP-1 can act as a coactivator of NF-B in vivo (18) . Neither the nuclear translocation nor the DNA binding ability of NF-B was affected in PARP-1(Ϫ/Ϫ) cells (18) . However, PARP-1 directly interacted with both subunits of NF-B (p65 and p50) in vitro and in vivo (18, 20) . Remarkably, the enzymatic activity of PARP-1 was not required for full activation of NF-B in response to various stimuli in vivo (20) . In addition, PARP-1 directly interacted with p300 and synergistically coactivated NF-B-dependent transcription (8) . Tulin and Spradling (21) recently found that Drosophila mutants lacking normal PARP-1 levels display immune defects similar to mice lacking the NF-B subunit p50. Their results imply that the role of PARP-1 in NF-B-dependent gene expression during immune responses has been conserved during evolution. Because NF-B-dependent gene expression requires post-translational modifications (22) , we decided to test whether the coactivator activity of PARP-1 might also be regulated by post-translational modifications. We show here that PARP-1-dependent gene expression not only requires the enzymatic activity of p300/CBP but also that PARP-1 itself is acetylated in vivo in response to inflammatory stimuli. Acetylation sites were mapped in vitro and in vivo to Lys-498, Lys-505, Lys-508, Lys-521, and Lys-524. Furthermore, acetylation of PARP-1 at these lysines is required for the interaction with p50 and the transcriptional activation of NF-B in response to inflammatory stimuli. Interestingly, the synergistic coactivation of PARP-1, p300, and also the Mediator complex was dependent on acetylation of PARP-1. Moreover, PARP-1 interacted with and is potentially deacetylated in vivo by class I HDACs. PARP-1-dependent transcriptional activation of NF-B was negatively regulated by HDACs 1-3 in vivo. Together, these results support the hypothesis that acetylation of PARP-1 is important for its role as transcriptional coactivator and that the different physiological functions of PARP-1 might be in general regulated by post-translational modifications in a stimulus-dependent manner.
MATERIALS AND METHODS
Reagents-Recombinant TNF␣ was obtained from R&D Systems. Phorbol esters and mouse interferon-␥ was purchased from Sigma. LPS (Escherichia coli, O26:B6) prepared by phenol extraction was purchased from Sigma and prepared as dispersed sonicate in endotoxin-free water before diluting to a final concentration in supplemented media. Nonfat dry milk was obtained from Migros (Switzerland). Nitrocellulose membranes were purchased from Osmonics Inc. Tosyl-activated Dynabeads were purchased from Dynal Biotech GmbH.
Plasmids-GST-PARP-1 and GST-p50 full-length expression vectors, CMV-PARP-1, and CMV-p300 expression vectors were described in Hassa et al. (8) and Covic et al. (16) . The CMV expression vectors for the different Mediator subunits were generated by PCR or were a generous gift from Dr. L. Freedman (Merck Research Laboratories, West Point, NY). The CMV expression vectors for Myc-tagged HDACs 1-3 were created by PCR. The CMV expression vectors for FLAG or hemagglutinin-tagged HDAC 4 -6 were kind gifts from Dr. S. L. Schreiber (Harvard University, Cambridge, MA). The expression vectors for CDK8/cyclin C and subunits of TFIID and TFIIF were kind gifts from Dr. M. Otsuka (University of Tokyo, Japan), Dr. Z. F. Burton (Michigan State University, East Lansing, MI), and Dr. G. Napolitano (University of Naples "Frederico II," Naples, Italy). NF-B-dependent luciferase reporter constructs for MIP-2 (MIP-2 (Ϫ531/wt and MIP-2 (-531/ mutB)-Luc) and iNOS (iNOS (1485/ϩ31wt)-Luc and iNOS(1485/ ϩ31-mutB)-Luc) were generous gifts from Dr. H.-J. Kwon, (Yonsei University, Seoul, Korea) and Dr. M. A. Perrella (Harvard School of Public Health, Boston, MA) and are described in Perrella et al. (23) and Kim et al. (24) . pphRSV-nt-␤-galactosidase is described in Hassa et al. (20) . The baculovirus for CDK8 and cyclin C was a generous gift from Dr. R. Pinhero (University of Guelph, Ontario, Canada) (25) . The baculovirus for human p300 and mouse CBP was a generous gift from Dr. W. L. Kraus (Cornell University, New York) and Dr. D. Thanos (Institute of Molecular Biology and Genetics, Alexander Fleming Biomedical Sciences Research Center, Athens, Greece). The baculovirus for PARP-1 full-length and different domains were created by PCR using the PAK-8/9 system (BD Biosciences). GST-fusion expression vectors for different domains of PARP-1 were created by PCR. The PARP-1 mutant constructs were obtained by site-directed mutagenesis and confirmed by sequencing.
Mice Breeding Conditions, Cell Culture, and Transient Transfections-129S/EV-PARP-1(ϩ/ϩ) and 129S/EV-PARP-1(Ϫ/Ϫ) mice were bred under specified pathogen-free conditions. The initial 129S/ EV-PARP-1(ϩ/ϩ) and 129S/EV-PARP-1(Ϫ/Ϫ) mice breeding pairs were a kind gift from Dr. Z. Q. Wang (26) (International Agency for Research on Cancer, Lyon, France). Primary macrophage cells were isolated from fresh littermates of 129S/EV-PARP-1(ϩ/ϩ) and 129S/ EV-PARP-1(Ϫ/Ϫ) mice (20, 26) according to an isolation procedure described in Petrilli et al. (19) , and human monocyte/macrophage-like THP-1 cells and Jurkat-T cells were grown in Hepes-buffered RPMIGlutamax-I (Invitrogen) containing 10% fetal calf serum U. S.-certified (Invitrogen) and supplemented with 50 units/ml penicillin, 50 g/ml streptomycin (Invitrogen), 1 mM sodium pyruvate, 0.05 mM ␤-mercaptoethanol, and minimum Eagle's medium-nonessential amino acids. Primary mouse fibroblast cells were grown in Hepes-buffered Dulbecco's modified Eagle's medium-Glutamax-I (Invitrogen) containing 4.5 g/liter glucose, 10% fetal calf serum U. S.-certified (Invitrogen) and supplemented with 50 units/ml penicillin, 50 g/ml streptomycin (Invitrogen), 1 mM sodium pyruvate, 0.05 mM ␤-mercaptoethanol, and minimum Eagle's medium-nonessential amino acids. HEK293 cells were grown in Hepes-buffered Dulbecco's modified Eagle's medium-Glutamax-I (Invitrogen) containing 4.5 g/liter glucose and 10% fetal calf serum U. S.-certified (Invitrogen) and supplemented with 50 units/ml penicillin, 50 g/ml streptomycin (Invitrogen), and minimum Eagle's medium-nonessential amino acids. For luciferase reporter assays, cells were grown in 24-or 48-well dishes. Cells were transfected using calcium phosphate or polyethyleneimine procedures (as described in Refs. [27] [28] [29] [30] except that primary cells were grown for 12 h in RPMI medium containing 2% fetal calf serum before stimulation with TNF␣ or LPS/ IFN␥. The amount of DNA indicated in the figure legends was calculated for 10 ml of medium. Total amounts of DNA and equal molar ratios of promoters were kept constant in all set-ups by using empty vectors. For primary cells only cell passages 1-4 were used for transfection experiments. Because of differences in transfection efficiencies, an expression plasmid of ␤-galactosidase (pph-RSV-nt-␤-Gal) was co-transfected as a transfection efficiency control, and luciferase activities were normalized based on ␤-galactosidase activity. Luciferase activity was measured as previously described in Hottiger et al. (27) . For further experimental procedures see the supplemental material. A, primary PARP-1(ϩ/ϩ) or PARP-1(Ϫ/Ϫ) macrophages were treated with LPS (0.1 g/ml) as indicated, and the expression of hypoxanthine-guanine phosphoribosyltransferase (HPRT), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and NF-B-dependent genes KC, MIP-2, iNOS, IB␣ and interleukin-6 (IL-6) was assessed by reverse transcription-PCR. B, equal amounts of total cell extracts from primary PARP-1(ϩ/ϩ) and PARP-1(Ϫ/Ϫ) lung fibroblasts or primary PARP-1(ϩ/ϩ) and PARP-1(Ϫ/Ϫ) macrophages were resolved by SDS-PAGE followed by immunoblot analysis using anti-p300, anti-PARP-1, anti-PCAF, or anti-␣-tubulin antibodies. C and D, primary PARP-1(Ϫ/Ϫ) macrophages were cotransfected with RSV-nt-␤-Gal (300 ng), expression vectors for PARP-1 (2 g), and wild type (WT) or an enzymatic mutant (Mut) of p300 (2 g) along with a luciferase reporter under the control of the endogenous MIP-2 (1 g) or iNOS (3 g) promoters; cells were subsequently treated for 4 h with TNF␣ (10 ng/ml) or LPS/IFN␥ (0.05 g/ml/100 units) in the simultaneous presence or absence of low doses of deacetylase inhibitors (10 nM TSA/200 M NAM). Cells were harvested 24 h after transfection, and NF-B-dependent gene expression was determined. The indicated activation was determined by the ratio of the relative luciferase activity measured for the promoters containing wild type B sites (black bars) or mutB sites (white bars) after stimulation. The ratio
RESULTS

PARP-1 Requires the Enzymatic Activity of p300 for Full NF-Bdependent Transcriptional Activity and Is Acetylated in
Vivo by p300/ CBP upon Stimulation-Because the coactivator activity of PARP-1 for NF-B-dependent gene expression is dependent on the stimuli and cell type (17), we first tested which NF-B-dependent genes are impaired in freshly isolated primary PARP-1(Ϫ/Ϫ) macrophages. Primary PARP-1(ϩ/ϩ) or PARP-1(Ϫ/Ϫ) macrophages were treated with LPS as indicated, and the expression of NF-B-dependent genes was assessed by reverse transcription-PCR (Fig. 1A) . The experiments revealed that LPS-induced levels of KC, MIP-2, and iNOS were impaired in PARP-1(Ϫ/Ϫ) cells (Fig. 1A) . The expression of IB␣ and interleukin-6 (IL-6) was not reduced (Fig. 1A) , indicating that only a subset of NF-B-dependent genes requires PARP-1 for gene induction in these cells. Similar results were obtained when cells were stimulated with TNF␣ (data not shown). To confirm that the expression levels of histone acetyltransferases are not reduced in primary PARP-1 (Ϫ/Ϫ) cells, we tested the protein levels of p300 and PCAF by immunoblot analysis using anti-PARP-1, anti-p300, or anti-PCAF antibodies. The endogenous protein levels of p300 and PCAF were not impaired in freshly isolated primary PARP-1(Ϫ/Ϫ) lung fibroblast or macrophage cells (Fig. 1B) .
PARP-1 and p300/CBP were shown to form a complex and function synergistically to enhance NF-B-mediated gene expression (8) . To test whether the synergistic coactivation of NF-B-mediated transactivation by PARP-1 and p300/CBP might require the enzymatic activity of p300/CBP, we transfected PARP-1(Ϫ/Ϫ) cells with expression vectors for PARP-1 and wild type or an enzymatic mutant of p300 along with a luciferase reporter under the control of the endogenous MIP-2 or iNOS promoters, shown to be PARP-1-dependent. Cells were subsequently treated with TNF␣ or LPS/IFN␥ in the simultaneous presence or absence of low doses of deacetylase inhibitors (TSA and nicotinamide (NAM)) ( Fig. 1, C and D) . Coexpression of wild type p300 with PARP-1 in PARP-1(Ϫ/Ϫ) cells resulted in a highly synergistic enhancement of transcription regulated from both MIP-2 and iNOS promoters upon stimulation (Fig. 1, C and D) . However, the cooperativity between p300 and PARP-1 was severely impaired when an enzymatic mutant of p300 FIGURE 1-continued obtained for untreated cells was arbitrarily set to 1. Error bars indicate S.E. of three independent experiments. E and F, primary PARP-1(ϩ/ϩ) and PARP-1(Ϫ/Ϫ) macrophages were repeatedly transfected with scrambled-or p300-siRNA targeting vector DNA (30 g) as indicated and then transfected and treated as indicated and described in D. The indicated activation was determined as described in D. G, equal amounts of total cell extracts from primary macrophages repeatedly transfected with scrambled-or p300-siRNA targeting vector DNA (30 g) as indicated were resolved by SDS-PAGE followed by immunoblot analysis using anti-p300 or anti-␣-tubulin antibodies. H, THP-1 or Jurkat-T cells were treated as indicated with LPS (0.2 g/ml) or phorbol ester (10 nM) and simultaneously with or without deacetylase inhibitors (100 nM TSA/400 M NAM) for 30 min. PARP-1 was immunoprecipitated (IP) under high salt conditions from nuclear extracts, and the presence of acetylated forms of PARP-1 was subsequently tested by immunoblot analysis using anti-AcK or anti-PARP-1 antibodies. PMA, phorbol 12-myristate 13-acetate. I, left panel, 293 cells were repeatedly transfected with scrambled-, p300-, or CBP-siRNA targeting vector DNA (30 g) and treated as indicated. PARP-1 was immunoprecipitated under high salt conditions from nuclear extracts, and the presence of acetylated forms of PARP-1 was subsequently tested by immunoblot analysis using anti-AcK or anti-PARP-1 antibodies. Right panel, equal amounts of total cell extracts from 293 cells repeatedly transfected with scrambled-or p300-siRNA targeting vector DNA (30 g) as indicated were resolved by SDS-PAGE followed by immunoblot analysis using anti-p300 or anti-␣-tubulin antibodies. DECEMBER 9, 2005 • VOLUME 280 • NUMBER 49 was coexpressed. The most striking differences between wild type and the enzymatic mutant of p300 were observed in the presence of low doses of deacetylase inhibitors (Fig. 1, C and D) . The same transfection experiments with a reporter gene under the control of mutated B sites revealed that the observed cooperative effect of p300 and PARP-1 was mainly NF-B-specific (Fig. 1, C and D) . To further confirm these FIGURE 2. PARP-1 is acetylated in vitro and in vivo at Lys-498, Lys-505, Lys-508, Lys-521, and Lys-524 by p300/CBP upon stimulation. A, recombinant purified full-length PARP-1 was incubated with recombinant purified full-length p300 or CBP in the presence of radioactive labeled acetyl-CoA and resolved by SDS-PAGE followed by autoradiography. B, baculo-purified PARP-1 fragments corresponding to amino acids (aa) 1-214, 215-372, 373-525, 525-656, or 657-1014 were incubated with recombinant purified full-length p300 or CBP in the presence of radioactive labeled acetyl-CoA and resolved by SDS-PAGE followed by autoradiography. C, recombinant purified full-length PARP-1 wild type and two mutant forms of PARP-1; mutKTR (K498R/K521R/K524R) and mutKQR (K498R/K505R/K508R/K521R/K524R) were incubated with recombinant purified full-length p300 or CBP in the presence of radioactive labeled acetyl-CoA and resolved by SDS-PAGE followed by autoradiography. D, Myc-tagged PARP-1 wild type (WT) or mutant mutKQR were overexpressed in 293 cells and treated as indicated with TNF␣ (10 ng/ml) and/or deacetylase inhibitors (100 nM TSA/400 M NAM) for 30 min. Myc-tagged PARP-1 wild type or mutant mutKQR was then immunoprecipitated (IP) under high salt conditions from nuclear extracts of 293 cells, and the presence of acetylated forms of PARP-1 was subsequently tested by immunoblot analysis (IB) using anti-AcK or anti-PARP-1 antibodies. E, the same experiments were repeated in the presence of increasing amounts of overexpressed p300. Immunoblot of p300 input is shown in the upper panels results, the same experiments were repeated in the presence of different p300-siRNA targeting vectors (Fig. 1, E and F) . These experiments revealed that the presence of endogenous p300 is required for PARP-1-dependent coactivation of NF-B-dependent gene expression (Fig. 1, E and F). Together these results indicate that the enzymatic activity of p300/CBP is required for NF-B-dependent transactivation of extrachromosomal templates upon treatment with inflammatory stimuli. p300 and CBP are known to modify a variety of proteins, such as histones and transcription factors (31) . To investigate whether endogenous PARP-1 itself might be acetylated by p300/CBP in vivo, we immunoprecipitated endogenous PARP-1 under high salt conditions from nuclear extracts of THP-1 or Jurkat-T cells upon treatment with the indicated stimuli (LPS or TNF␣) in the simultaneous presence or absence of deacetylase inhibitors (Fig. 1H, left and right panels) . Possible acetylation of PARP-1 was analyzed by immunoblot analysis using an anti-AcK antibody. Endogenous PARP-1 was acetylated in vivo only in the presence of deacetylase inhibitors upon stimulation of these cells (Fig. 1H, left and right panels) . Next we tested whether the observed acetylation of PARP-1 is dependent on p300/CBP. 293 cells were cotransfected with a control-siRNA vector and/or different siRNA targeting vectors for p300 or CBP. Endogenous PARP-1 was immunoprecipitated under high salt conditions from nuclear extracts of 293 cells upon treatment with TNF␣ in the presence of deacetylase inhibitors (Fig. 1H, left and right panels) . These results revealed that endogenous PARP-1 was only acetylated in vivo upon stimulation in presence of endogenous p300 or CBP (Fig. 1I) .
PARP-1 Is Acetylated by p300/CBP
PARP-1 Is Acetylated by p300/CBP in Vitro and in Vivo at
Lys-498, Lys-505, Lys-508, Lys-521, and Lys-524-Next, we tested whether PARP-1 can be acetylated by p300 or CBP in vitro. Recombinant-purified full-length PARP-1 was incubated with recombinant-purified fulllength p300 or CBP in the presence of radioactive labeled acetyl-CoA and resolved by SDS-PAGE followed by autoradiography analysis (Fig.  2A) . PARP-1 was strongly acetylated in vitro by p300 or CBP (Fig. 2A) . To map the domains within PARP-1 subjected to acetylation by p300 and CBP, the same in vitro acetylation assay was repeated with different PARP-1 fragments corresponding to amino acids 1-214, 215-372, 373-525, 525-656, or 657-1014. These experiments revealed that p300 and CBP strongly acetylated the PARP-1 domain corresponding to amino acids 373-525 (Fig. 2B, left and right panels) . Interestingly, a longer autoradiography exposure revealed that the domain corresponding to amino acids 1-214 of PARP-1 and to the small product of caspase cleaved PARP-1, was weakly acetylated by p300 or CBP (supplemental information and data not shown). The physiological relevance of this finding is currently under investigation. To identify the lysines acetylated by p300/CBP within PARP-1, recombinant purified full-length PARP-1 was acetylated in vitro by p300 full-length and analyzed by microcapillary reverse-phase high performance liquid chromatography nanoelectrospray tandem mass spectrometry. Lys-498, Lys-505, Lys-508, Lys-521, and Lys-524 were identified as strong candidates for acetylation. To confirm that these lysines are the main acceptor sites, fulllength PARP-1 wild type or two PARP-1 mutant forms, mutKTR (K498R/K521R/K524R) and mutKQR (K498R/K505R/K508R/K521R/ K524R) were incubated with p300 or CBP in the presence of radioactive labeled acetyl-CoA and resolved by SDS-PAGE followed by autoradiography analysis (Fig. 2C) . These experiments confirmed that only the PARP-1 mutant harboring all five mutated lysines was no longer acetylated in vitro by p300 and CBP (Fig. 2C) . To investigate whether these lysines are also the main acceptor sites for acetylation in vivo by p300, we immunoprecipitated Myc-tagged PARP-1 wild type or mutant mut-KQR under high salt conditions from nuclear extracts of 293 cells upon treatment with the indicated stimuli in the presence or absence of deacetylase inhibitors (Fig. 2D) . The presence of acetylated forms of PARP-1 was tested by immunoblot analysis using an anti-AcK antibody. PARP-1 was acetylated in vivo at Lys-498, Lys-505, Lys-508, Lys-521, and Lys-524 in the presence of deacetylase inhibitors upon stimulation (Fig. 2D , also see the supplemental information). The same experiments performed in the presence of increasing amounts of overexpressed p300 suggested that these lysines are acetylated in vivo by p300 (Fig. 2E) .
Acetylation of PARP-1 at Lys-498, Lys-505, Lys-508, Lys-521, and Lys-524 Is Required in Vivo for Full NF-B-dependent Transcriptional Activity-To directly test whether acetylation of PARP-1 is required for NF-B-dependent transcriptional activity in vivo, we transfected PARP-1(Ϫ/Ϫ) cells with expression vectors for p300 and PARP-1 wild type or mutant mutKQR along with a luciferase reporter under the control of the endogenous MIP-2 or iNOS promoters. Cells were subsequently treated with the indicated stimuli (TNF␣ or LPS/IFN␥) in the simultaneous presence or absence of low doses of deacetylase inhibitors (Fig. 3,  A and B) . Coexpression of wild type p300 and wild type PARP-1 in PARP-1(Ϫ/Ϫ) cells caused a highly synergistic enhancement of transcription regulated from both MIP-2 and iNOS promoters upon stimulation (Fig. 3, A and B) . However, the cooperativity between p300 and PARP-1 was severely impaired when the PARP-1 mutant mutKQR was coexpressed. The most striking differences between PARP-1 wild type and the mutant mutKQR were observed in the presence of low doses of deacetylase inhibitors. The same transfection experiments with a reporter gene under the control of mutated B sites revealed that the observed induction was mainly NF-B-specific (Fig. 3, A and B; and supplemental information).
Pavri et al. (32) have very recently shown that PARP-1 can associate in vivo with the Mediator. Therefore, we repeated the same transfection experiments in the presence of overexpressed subunits of the Mediator complex. Coexpression of PARP-1 wild type, p300, and Mediator subunits in PARP-1(Ϫ/Ϫ) cells caused a synergistic enhancement of NF-Bdependent transcription, whereas no synergistic enhancement was observed when the mutant form of PARP-1, mutKQR, was coexpressed (Fig. 3, C and D) , indicating that acetylation of PARP-1 is also required for the transcriptional cooperativity between p300/CBP, Mediator, and PARP-1 on these promoters.
PARP-1 Interacts in Vivo with the Mediator Complex and in Vitro Directly with the Mediator Subunits CDK8 and DRIP150-To
further confirm these data and to investigate whether CDK8 or other subunits of the Mediator complex might directly interact with PARP-1, we first coexpressed tagged forms of different Mediator subunits in 293 cells (Fig. 4A) . Immunoprecipitation experiments using an anti-PARP-1 antibody revealed that PARP-1 interacted with the whole Mediator complex (Fig. 4A) . Next, we repeated these experiments with primary macrophages (Fig. 4B) . These experiments revealed that endogenous PARP-1 could indeed interact with the endogenous Mediator complex under physiological conditions (Fig. 4B) . DNA did not mediate the association of PARP-1 with the Mediator in the nucleus since the presence of ethidium bromide or DNase I did not affect PARP-1/Mediator interaction (data not shown). Surprisingly, whereas the interaction of PARP-1 with the core Mediator module was increased upon stimulation, the interaction of PARP-1 with CDK8 was decreased (Fig. 4, A and  B) . CDK8 is thought to act mainly as a repressor sub-module of the Mediator complex (32) .
Because these results strongly suggested that PARP-1 would directly interact with at least one of these Mediator subunits, recombinant purified GST-PARP-1 full-length was bound to glutathione beads followed by incubation with in vitro translated and radioactive-labeled Mediator PARP-1 Is Acetylated by p300/CBP DECEMBER 9, 2005 • VOLUME 280 • NUMBER 49 subunits as indicated in Fig. 4C . After extensive washes, bound proteins were resolved by SDS-PAGE followed by autoradiography analysis for Mediator subunits. PARP-1 directly bound to CDK8 and MED14, although to a low extent, but not to the other tested subunits (Fig. 4C) . We next tested whether PARP-1 might also directly interact with other components of the RNA polymerase II machinery. Recombinant purified HMG(YI), CDK8, cyclin C, TFIIF/RAP74, TFIIF/RAP30, TATA box-binding protein (TBP), and TBP-associated factors fused to GST were bound to glutathione beads followed by incubation with recombinant baculo-purified PARP-1 (Fig. 4D, left and right panels) . After extensive washes, bound proteins were resolved by SDS-PAGE followed by immunoblot analysis for PARP-1. PARP-1 was able to bind directly to HMG(YI), CDK8, and TFIIF/RAP74 but not to the other factors tested (Fig. 4D, left and right panels) .
Acetylation of PARP-1 at Lys-498, Lys-505, Lys-508, Lys-521, and
Lys-524 Stabilizes the Interaction of PARP-1 with p50-To investigate whether acetylation of PARP-1 mechanistically influences protein-protein interactions, we first tested which of the interaction partners associates with the acetylated domain of PARP-1. Different domains of PARP-1 fused to GST were bound to glutathione beads and incubated with purified p300, PARP-1, CDK8/cyclin C, p65, p50, TFIIF/RAP74 or in vitro transcribed/translated and radioactive-labeled MED14 (Fig. 5, A  and B) . After extensive washes, bound proteins were resolved by SDS-PAGE followed by immunoblot analysis with the indicated antibodies (Fig. 5A) or autoradiography (Fig. 5B) . p300, PARP-1, CDK8, p65, p50, TFIIF/RAP74, and MED14 bound to different domains of PARP-1 as schematically drawn in Fig. 5C . PARP-1 interacted with a region between amino acids 1 and 214 as well as between amino acids 465 and under physiological salt conditions from nuclear extracts using an anti-PARP-1 antibody and tested for PARP-1 and Myc-or FLAG-tagged Mediator subunits, p300, and CDK8 by immunoblot analysis using anti-PARP-1, anti-p300, anti-CDK8, anti-Myc, or anti-FLAG antibodies. C, control IgG; P1, anti-PARP-1. B, primary macrophages were treated as indicated with LPS (0.2 g/ml) for 1 h. PARP-1 was immunoprecipitated under physiological salt conditions from nuclear extracts, and the presence of Mediator subunits was subsequently tested by immunoblot analysis using anti-MED1, anti-MED6 anti-TRAP150, anti-CDK8, or anti-PARP-1 antibodies. C, GST pull down assays under physiological salt conditions with PARP-1 full-length fused to GST (3 g GST fusion protein) and the indicated in vitro transcribed/translated Mediator subunits. Bound proteins were resolved by SDS-PAGE followed by autoradiography. The Coomassie control gel is shown in the left panel. D, GST pull down assays under physiological salt conditions with the indicated general transcription factors and CDK8/cyclin C fused to GST (1-4 g of GST fusion protein) and baculo-purified PARP-1 (0.5 g input). Bound proteins were resolved by SDS-PAGE followed by immunoblot analysis using anti-PARP-1 antibodies (upper panel). The corresponding Coomassie control gel is shown in the lower panel. TBP, TATA box-binding protein. DECEMBER 9, 2005 • VOLUME 280 • NUMBER 49 -1 with p50 but not p65 or PARP-1. A and B , mapping of the interaction domains in PARP-1. Shown are GST pull down assays under high salt conditions with PARP-1 fragments fused to GST (1-3 g of protein) as indicated and recombinant purified p300 (2 g), PARP-1 (0.3 g), RAP74 (1 g), CDK8 (1 g), cyclin C (0.5 g), p65 (0.5 g), and p50 (0.5 g) (A) or in vitro transcribed/translated MED14 (B). Bound proteins were resolved by SDS-PAGE followed by immunoblot analysis with the corresponding antibodies (A) or autoradiography (B). The corresponding Coomassie control gel is shown in the lower panels. aa, amino acids. C, schematic picture of the PARP-1 interaction map: ZF I and ZFII, zinc finger 1 and 2; NLS, nuclear localization signal; HTH, helix turn helix domain, BRCT, C-terminal domain of a breast cancer susceptibility protein (BRCA); WGR, central WGR motif-containing domain;PADR1, PARP regulatory domain; CC, catalytic center. D and E, acetylation-dependent interaction of PARP-1 and p50. PARP-1 (D) or p50 (E) fused to GST (3 g/2 g) were incubated with in vitro acetylated or non-acetylated baculo-purified PARP-1 wild type (WT) or mutant form mutKQR (500 ng) in 524 (Fig. 5C) . MED14 was the only tested protein that bound to the BRCT (carboxyl-terminal domain of a breast cancer susceptibility protein (BRCA)) domain of PARP-1. We have previously shown that p50 and p65 interact with a region between amino acids 341 and 531 of PARP-1 (20) . In addition, p50 interacted also with a region between amino acids 1 and 140 containing the zinc finger I. Our more detailed interaction analysis suggests that p65 would interact with a region between amino acids 341 and 383 of PARP-1. p50 would interact with zinc finger I or zinc finger II and with a region between amino acids 477 and 524 (Fig. 5C) . Together, these experiments revealed that only the interaction of PARP-1 with PARP-1 itself or p50 might be influenced by acetylation of PARP-1.
PARP-1 Is Acetylated by p300/CBP
To test this hypothesis, recombinant purified PARP-1 or p50 fused to GST were bound to glutathione beads and incubated with non-acetylated or in vitro acetylated purified PARP-1 wild type and the mutant form mutKQR in the presence of increasing concentrations of NaCl as indicated (Fig. 5, D and E) . After extensive washes, bound proteins were resolved by SDS-PAGE followed by immunoblot analysis for PARP-1 (Fig. 5, D and E) . No significant differences between the acetylated or non-acetylated form of PARP-1 were observed for the dimerization or potential tetramerization of PARP-1 (Fig. 5D) . Surprisingly, in vitro acetylated PARP-1 bound significantly better to p50 than did the nonacetylated PARP-1 (Fig. 5E) . These results suggest that PARP-1 would dimerize or potentially tetramerize through the regions between amino acid 1 and 214 as well as between amino acid 465 and 497, whereas the region between amino acid 477 and 524 is required for acetylation-dependent interaction with p50 (Fig. 5C ).
To confirm these in vitro data and to investigate whether acetylation would influence the stimuli-dependent complex formation between subunits of NF-B and PARP-1 in vivo, we coimmunoprecipitated the NF-B subunits p65 and p50 from nuclear extracts upon treatment of THP-1 with LPS in the presence or absence of deacetylase or phosphatase inhibitors (Fig. 5F, left and right panels) and tested the presence of PARP-1 by immunoblot analysis using anti-PARP-1 antibodies. Remarkably, PARP-1 bound significantly better to p65 when cells were simultaneously treated with LPS and phosphatase inhibitors (Fig. 5F , left panel), whereas p50 bound significantly better to PARP-1 upon simultaneous treatment with LPS and deacetylase inhibitors (Fig. 5F, right  panel) . No significant differences between deacetylase or phosphatase inhibitors were observed for the interaction between p50 and p65 (Fig.  5F, left and right panels) . Taken together, these results suggest that phosphorylation might mainly enhance the interaction between p65 and PARP-1, whereas acetylation mainly enhances the interaction between p50 and PARP-1.
PARP-1 Interacts with Members of HDAC Class I and Is Potentially Deacetylated by HDACs 1-3 in
Vivo-Because acetylation of proteins is known to be a reversible modification in vivo, we next tested whether PARP-1 might physically interact with HDACs in vivo. Because of the low quality of commercially available anti-HDAC antibodies, we decided to perform these experiments with overexpressed Myc-or FLAG-tagged HDACs. We coimmunoprecipitated PARP-1 complexes from nuclear extracts of untreated 293 cells overexpressing Myc-tagged versions of HDAC-1, HDAC-2, or HDAC-3 ( Fig. 6A) and FLAG-tagged versions of HDAC-4, HDAC-5 or HDAC-6 (Fig. 6B ) and tested the presence of increasing concentrations of NaCl (125 mM NaCl, 25 mM potassium acetate to 225 mM NaCl, 25 mM potassium acetate) as indicated. Bound proteins were resolved by SDS-PAGE followed by immunoblot analysis using a anti-PARP-1 antibody. F, acetylation and stimuli-dependent complex formation of PARP-1 and subunits of NF-B in vivo. NF-B subunits p65 and p50 were coimmunoprecipitated (IP) from nuclear extracts upon treatment of THP-1 with LPS in the presence or absence of deacetylase or phosphatase inhibitors (left and right panels) and tested for the presence of p50, p65, and PARP-1 by immunoblot analysis using anti-p50, anti-p65, and anti-PARP-1 antibodies. C, control. vivo by HDAC-1 HDAC-2, or HDAC-3 . A-F, primary PARP-1(Ϫ/Ϫ) macrophages were cotransfected with expression vectors for RSV-nt-␤-Gal (300 ng), PARP-1 wild type (WT) or mutant mutKQR (2 g), p300 (2 g), HDAC-1, HDAC-2, or HDAC-3 (2.5 g each) along with a luciferase reporter under the control of the endogenous MIP-2 (1 g) (A-C) or iNOS promoters (3 g) (D-F); cells were subsequently treated for 4 h with TNF␣ (10 ng/ml) or LPS/IFN␥ (0.05 g/ml/100 units) in the simultaneous presence of low doses of deacetylase inhibitor (500 M NAM). Cells were harvested 24 h after transfection, and NF-B-dependent gene expression was determined as described in Fig. 1C . DECEMBER 9, 2005 • VOLUME 280 • NUMBER 49 presence of these HDACs by immunoblot analysis using anti-PARP-1, anti-Myc, or anti-FLAG antibodies. Interestingly, PARP-1 interacted with HDAC-1, HDAC-2, and HDAC-3 but not with HDAC-4, HDAC-5, or HDAC-6 (Fig. 6, A and B) . DNA did not mediate the association of PARP-1 with HDACs since the presence of ethidium bromide or DNase I did not affect the interaction (data not shown). Because these results suggested that PARP-1 would directly interact with at least one of these HDACs, GST-PARP-1 full-length was bound to glutathione beads and incubated with in vitro translated and radioactive-labeled HDAC class I members HDAC-1, HDAC-2, HDAC-3, or HDAC-8 (Fig.  6C) . After extensive washes, bound proteins were resolved by SDS-PAGE followed by autoradiography analysis for HDACs. PARP-1 bound directly to HDAC-1, HDAC-2, and HDAC-3 but not to HDAC-8 (Fig. 6C) .
PARP-1 Is Acetylated by p300/CBP
To investigate whether PARP-1 might be deacetylated by HDAC-1, HDAC-2, or HDAC-3 in vivo, FLAG-tagged PARP-1 wild type was coexpressed with increasing amounts of Myc-tagged HDAC-1, HDAC-2, or HDAC-3 ( Fig. 6D) and hemagglutinin-tagged HDAC-4 or HDAC-5 in 293 cells (Fig. 6E) . FLAG-tagged PARP-1 was immunoprecipitated from nuclear extracts under high salt conditions upon treatment of cells with TNF␣ and NAM. The presence of acetylated forms of PARP-1 was tested by immunoblot analysis using anti-AcK or anti-FLAG antibodies. These experiments revealed that PARP-1 might be deacetylated in vivo by HDAC-1, HDAC-2, or HDAC-3 (Fig. 6, D and E) .
PARP-1-dependent Transcriptional Activation of NF-B Seems to Be Negatively Regulated by HDACs 1-3 in
Vivo-Next, we tested which HDAC has the strongest influence on the transcriptional coactivator activity of PARP-1 and might therefore also act functionally as a deacetylase for PARP-1 in vivo. PARP-1(Ϫ/Ϫ) cells were cotransfected with expression vectors for PARP-1 wild type or PARP-1 mutant form; that is, mutKQR, p300, HDAC-1, HDAC-2, or HDAC-3 along with a luciferase reporter under the control of the endogenous MIP-2 (Fig. 7, A-C) or iNOS promoters (Fig. 7, D-F) . Cells were simultaneously treated with the indicated stimuli (TNF␣ or LPS/IFN␥) and low doses of deacetylase inhibitors (Fig. 7,  A-F) . Coexpression of p300 with HDAC-1, HDAC-2, or HDAC-3 in the absence of PARP-1 resulted in a reduced activation of NF-B-dependent transcriptional activation (Fig. 7, A-F) . No significant differences between HDAC-1, HDAC-2, or HDAC-3 were observed in the absence of PARP-1 for either MIP-2 or iNOS promoters (Fig. 7, A-F) , indicating that the residual activation of NF-B in PARP-1(Ϫ/Ϫ) cells in the absence of PARP-1 is equally repressed by HDAC-1, HDAC-2, or HDAC-3. Similar results were obtained in presence of PARP-1 wild type, although the repression by HDAC-2 was weaker when compared with HDAC-1 and HDAC-3 (Fig. 7,  A-F) . Remarkably, the repression by HDAC-1, HDAC-2, or HDAC-3 was strongly reduced when HDAC-1 HDAC-2, or HDAC-3 was coexpressed with PARP-1 mutant mutKQR (Fig. 7, A-F) . Together these results suggest that HDAC-1, HDAC-2, and HDAC-3 might repress NF-B-dependent transcription in part through deacetylation of PARP-1.
DISCUSSION
Growing experimental evidence suggests that PARP-1 can function as a promoter-specific coactivator (17) . PARP-1 was also identified as an interaction partner not only of NF-B but also of several sequencespecific transcription factors and cofactors including E2F1, Oct-1, and PC3/topoisomerase-I (17, 33) and has been shown to increase the transcriptional activity of these transcription factors (17) . In 1997 Meisterernst et al. (34) identified human PARP-1 as one active component of the upstream stimulatory activity (USA)-derived positive cofactor complex PC-1 (34). The crude precursor human USA fraction consists of PC1/PARP-1, PC2/Mediator-like complex, PC3/topoisomerase-I, PC4/ single-stranded DNA-binding protein, PC52, PC6, and HMG2 (34, 35) . Earlier studies showed that full activation of transcription by NF-B, Sp1, and Oct-1 in cell-free systems required a crude precursor USA coactivator fraction in addition to general transcription factors (36) . Because PC1/PARP-1, PC3, and PC4 are all sequence-unspecific DNAbinding proteins, it was suggested that PC1/PARP-1 provide together with the other USA-derived positive cofactors PC3, PC4, PC52, and HMG2 a mainly structural/architectural role in assembling and stabilizing the pre-initiation complex by affecting the accessibility of RNA polymerase II to chromatin (17, 34, 35, 37) .
The aim of this study was to investigate whether the coactivator activity of PARP-1 might be regulated by post-translational modifications such as acetylation. We provide both biochemical and functional evidence that acetylation of PARP-1 is required for its NF-B coactivator activity.
PARP-1 Requires the Enzymatic Activity of p300 for Full NF-Bdependent
Transcriptional Activity-Several reports demonstrated that coactivator activity of PARP-1 for NF-B-dependent gene expression seems to be dependent on the stimuli and cell type (17) . We observed an impaired expression in primary PARP-1(Ϫ/Ϫ) macrophages of iNOS, KC, and MIP-2 genes but not of IB␣ and IL-6 upon stimulation with TNF␣ or LPS/IFN␥, indicating that PARP-1 acts in a promoter-specific manner, similar to other coactivators of NF-B such as CARM1 (16) . PARP-1 and p300/CBP were shown to form a complex and function synergistically to enhance NF-B-mediated gene expression (8) . Moreover, we recently provided evidence that the enzymatic activities of p300/CBP and protein arginine methyltransferase CARM1 are required for NF-B-dependent gene expression in vivo (16) . NF-B-dependent reporter gene analysis using the PARP-1-dependent MIP-2 and iNOS promoters revealed that the cooperativity between p300 and PARP-1 was severely impaired when an enzymatic mutant of p300 was coexpressed, indicating that the enzymatic activity of p300/CBP is required for NF-B-dependent transactivation of PARP-1-dependent promoters upon treatment with inflammatory stimuli.
PARP-1 Is Acetylated in Vivo at Lys-498, Lys-505, Lys-508, Lys-521, and Lys-524 by p300/CBP upon Stimulation-Growing experimental evidence has accumulated that NF-B-dependent gene expression is also regulated by post-translational modifications such acetylation (22) . This acetylation-dependent regulation was shown to occur at multiple levels (38) . Acetylation of histones regulates the NF-B-dependent gene accessibility (22) . Moreover, direct acetylation of the NF-B subunits p65 and p50 was shown to regulate transcriptional activation of NF-B (39 -41) . Finally, other acetylation events were suggested to temporarily modulate the duration of NF-B presence in the nucleus and DNA binding activity as well as protein-protein interactions with several cofactors involved in the transcriptional activity of NF-B (22, 38) . It was recently reported that the USA-derived positive cofactor PC4 is specifically acetylated by p300, thereby stimulating its double-stranded DNA binding activity which correlates with its coactivation activity (42, 43) . Here we show that PARP-1 is acetylated in vitro and in vivo by p300 and CBP. Combined analysis by microcapillary reverse-phase high performance liquid chromatography nanoelectrospray tandem mass spectrometry and coexpression of p300/CBP and PARP-1 wild type or mutant revealed that PARP-1 is acetylated in vivo at Lys-498, Lys-505, Lys-508, Lys-521, and Lys-524 by p300/CBP upon stimulation. In vitro acetylation experiments using purified recombinant PARP-1 wild type or mutant forms supported these in vivo observations.
Acetylation of PARP-1 at Lys-498, Lys-505, Lys-508, Lys-521, and Lys-524 Is Required for NF-B-dependent Transcriptional Activity in
Vivo-The importance of PARP-1 acetylation for NF-B-dependent transcription is supported by complementation experiments in primary PARP-
